JQUA JPMorgan U.S. Quality Factor ETF

Expense Ratio
0.12%
Dividend
1.05%
Previous close
$74.71
Est. 12 months change
+13.56%
Projected Price
$84.84

Profitability Metrics

Return on Equity (ROE)
45.48%
Return on Assets (ROA)
12.29%
Return on Invested Capital (ROIC)
40.32%
Weighted Average Cost of Capital (WACC)
9.35%
ROIC - WACC
30.97%
Updated : 2026-08-12 17:18 ET

Valuation Metrics

P/E Ratio
26.90
Forward P/E
19.87
PEG Ratio
2.25
Debt Current Ratio
1.82

Growth & Cash Flow

Gross Margin
59.34%
Operating Margin
29.63%
FCF Margin
25.09%
TTM Revenue Growth
29.11%
Projected 12M EPS Growth
35.34%

Price Change

Price % from 50 SMA
3.86%
Price % from 200 SMA
13.04%
6 Months
17.97%
1 Year
21.90%
2 Years
41.93%
The above metrics represent weighted averages, calculated using each stock's individual value weighted by its proportion of ETF holdings.

Top 10 Holdings

Stock TickerWeight
AVGO2.19%
MSFT2.15%
NVDA2.13%
AAPL2.10%
GOOGL1.92%
AMD1.84%
META1.76%
MU1.75%
V1.73%
XOM1.69%

ETF Analysis

Fund Overview

JPMorgan U.S. Quality Factor ETF (JQUA) currently reports 304 stock positions (subject to change), placing it in the widely spread range by holdings breadth. The top line-up is AVGO (2.19%), MSFT (2.15%), NVDA (2.13%), with AVGO as the largest single weight at 2.19%. Together, the top three holdings account for 6.47%, which points to a relatively flat weight distribution where no single cluster of names dominates outcomes. The weight distribution suggests a portfolio designed to capture thematic upside while avoiding excessive dependence on any single name outside the largest positions.

Profitability & Capital Efficiency

Assessing the quality of returns on invested capital, ROIC is 40.32%, WACC is 9.35%, and the economic spread is 30.97%. On balance, the underlying businesses generate returns on capital that dramatically exceed their funding costs — a rare and powerful compounding dynamic. Supporting metrics show ROE at 45.48% and ROA at 12.29%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a portfolio with credible compounding capacity if current operating execution persists.

Valuation

The market currently prices the portfolio at trailing P/E of 26.90, forward P/E of 19.87, PEG of 2.25. The trailing and forward multiples diverge by a moderate amount, consistent with a market that sees improving earnings but is not extrapolating an aggressive growth path. The PEG ratio is consistent with a portfolio that is reasonably valued on a growth basis — not cheap, but not obviously expensive either. The current ratio of 1.82 is in an acceptable range, reflecting reasonable short-term financial health. Valuation and liquidity together frame a portfolio where the price paid today is a reasonable bet on earnings delivery — but not a margin-of-safety purchase at current levels.

Margins & Cash Generation

Looking at margins from gross to free cash flow, gross margin sits at 59.34%, operating margin at 29.63%, and free cash flow margin at 25.09%. Gross margins are constructive — not exceptional, but indicative of businesses with reasonable unit economics. At this level, operating margins reflect businesses that are scaling with discipline without dramatic cost pressure. Outstanding free cash flow margins signal businesses that convert revenues into cash at rates that support both reinvestment and shareholder returns. All three margin layers are constructive, pointing to a portfolio where quality of earnings is high and cash generation is reliable.

Growth & Forward Outlook

Projected 12-month EPS growth of 35.3% adds a powerful forward signal — analyst consensus expects earnings to accelerate materially, which, if delivered, could make current multiples look increasingly modest. Turning to growth and analyst expectations, TTM revenue growth of 29.11% pointing to sustained and broad-based revenue growth within the basket, while the estimated 12-month price change of 13.70%, where target prices point to mid-range appreciation potential from current levels. The distinction matters: revenue growth tells you what the businesses are doing, price targets tell you what analysts think the market will pay for it. Ultimately, the alignment between revenue momentum and analyst targets will depend on execution quality and the broader rate and sentiment environment. The estimated 12-month price change is a weighted composite of analyst price target estimates adjusted by each holding's ETF weight, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.

Conclusion

Strong Buy

The quantitative profile, taken as a whole, is above average on virtually every dimension that matters for long-term return generation.

The views expressed above are derived from quantitative data only and should not be relied upon as financial advice. Investment decisions should be based on your own research and risk tolerance.